AEGLEA BIOTHERAPEUTICS, INC. STOCK RESTRICTION AGREEMENTStock Restriction Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware
This Stock Restriction Agreement (this “Agreement”) is made and entered into as of March 10, 2015 (the “Effective Date”) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and (“Stockholder”).
PATENT LICENSE AGREEMENT AGREEMENT NO. PM1401601Patent License Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, ‘Party”).
Master Services AgreementMaster Services Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • North Carolina
This Master Services Agreement (this “Agreement”) dated December 24, 2013 (the “Effective Date”), between Aeglea Development Company, Inc., having a place of business at 815-A Brazos St. #101, Austin, TX 78701 (“Client”) and KBI Biopharma, Inc., having a place of business at 1101 Hamlin Road, Durham, North Carolina 27704 (“KBI Biopharma”) (Client and KBI Biopharma, each a “Party”, and collectively, the “Parties”).
AEGLEA BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT March 10, 2015Investor Rights Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Investor Rights Agreement (the “Agreement”) is entered into as of this 10th day of March 2015, by and among Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and each holder of the Company’s Series A Preferred Stock, $0.0001 par value per share (“Series A Preferred Stock”) and Series B Preferred Stock, $0.0001 par value per share (“Series B Preferred Stock”, referred to herein collectively with the Series A Preferred Stock as the “Preferred Stock”) listed on Schedule A (together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Section 6.1 below, the “Investors”).
SPONSORED RESEARCH AGREEMENT NO. UTA13-001113Sponsored Research Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”). Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.
CONSULTING AGREEMENTConsulting Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This Consulting Agreement (this “Agreement”), dated as of February 18, 2014, is entered into by and between Aeglea Development Company, Inc., a Delaware corporation (the “Company”), and George Georgiou (“Consultant”).
RE: Board Service Agreement Dear Russ:Board Service Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations
This letter sets forth the agreement between you and Aeglea BioTherapeutics, Inc. (the “Company”) regarding your Board service, effective as of June 15, 2015 (the “Effective Date”):
RECITALSCancer Research Grant Contract • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
Section C1.04 Conduct of Research or Service Provided. RECIPIENT understands that the Project must be conducted with full consideration for the ethical and medical implications of the research performed or services delivered and comply with all federal and state laws regarding the conduct of the research or service.
